Price Alert

Pacira BioSciences Inc. (PCRX)

NASDAQ: PCRX · Real-Time Price · USD

24.99

-0.05 (-0.20%)

At close: Aug 14, 2025, 3:59 PM

-0.20% (1D)

Bid	24.61
Market Cap	1.12B
Revenue (ttm)	705.85M
Net Income (ttm)	-127.46M
EPS (ttm)	-2.75
PE Ratio (ttm)	-9.09
Forward PE	7.41
Analyst	Buy

Ask	26.5
Volume	747,050
Avg. Volume (20D)	654,929
Open	24.77
Previous Close	25.04
Day's Range	24.70 - 25.35
52-Week Range	12.61 - 27.64
Beta	0.48

About PCRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PCRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PCRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Pacira BioSciences has released their quartely earnings on Aug 5, 2025:

Revenue of $181.1M misses estimates by $2.25M, with 1.73% YoY growth.

EPS of 0.74 exceeds estimates by 0.12, with -16.85% YoY decline.

Next Earnings Release

Pacira BioSciences Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

+14.67%

Pacira BioSciences shares are trading higher after... Unlock content with Pro Subscription

4 months ago

-0.82%

Pacira BioSciences shares are trading higher after the company announced settlement of litigation related to EXPAREL patents.

News

1 week ago · seekingalpha.com

Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript

Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Brendan P. Teehan - Chief Commercial Officer Frank D.

1 week ago · zacks.com

Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings

While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to ...

1 month ago · zacks.com

Is the Options Market Predicting a Spike in Pacira BioSciences Stock?

Investors need to pay close attention to PCRX stock based on the movements in the options market lately.

2 months ago · accessnewswire.com

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company"...

2 months ago · accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company"...

2 months ago · accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company"...